Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 10/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 10/20 | 0.45 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 5/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8717338 | 0.89 | ITGB3 (0.54) | ITGB3ITGA2BCALCRLCTSKCTSL | |
| SCHEMBL25186364 | 0.89 | ITGB3 (0.54) | ITGB3ITGA2BCALCRLCTSKCTSL | |
| SCHEMBL2896794 | 0.87 | ITGB3 (0.53) | ITGB3ITGA2BCALCRLCTSKCTSL | |
| SCHEMBL25183128 | 0.87 | ITGB3 (0.53) | ITGB3ITGA2BCALCRLCTSKCTSL | |
| SCHEMBL14580885 | 0.86 | CTSK (0.38) | CYP2D6ITGB3ITGA2BCALCRLCTSK | |
| SCHEMBL13030795 | 0.86 | CTSK (0.35) | CYP2D6ITGB3ITGA2BCALCRLCTSK | |
| SCHEMBL23879097 | 0.86 | HPGD (0.38) | CYP2D6ITGB3ITGA2BCTSKCTSL | |
| SCHEMBL24822362 | 0.86 | HPGD (0.38) | CYP2D6ITGB3ITGA2BCTSKCTSL | |
| SCHEMBL4933439 | 0.86 | CTSK (0.52) | ITGB3ITGA2BCTSKCTSLCTSB | |
| SCHEMBL26013230 | 0.84 | HPGD (0.38) | CYP2D6ITGB3ITGA2BCTSKCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501498-B2 | Mass tags for quantitative analyses | DH TECHNOLOGIES DEVELOPMENT PTE. LTD. (SG) | 2013-08-06 | — | — | US | disclosed |
| US-20100311175-A1 | MASS TAGS FOR QUANTITATIVE ANALYSES | Life Technologies Corporation (US) | 2010-12-09 | — | — | US | disclosed |
| US-20070048752-A1 | Mass tags for quantitative analyses | APPLERA CORPORATION (US) | 2007-03-01 | — | — | US | disclosed |
| EP-0559046-B1 | N-amidinopiperidinyl(3/4)- or N-amidino-1,4-Oxazinyl(2)-substituted sulfonamides, process for their preparation and use as thrombin inhibitors | HOFFMANN LA ROCHE (CH) | 2001-07-11 | — | — | EP | disclosed |
| EP-0559046-A1 | N-amidinopiperidinyl(3/4)- or N-amidino-1,4-Oxazinyl(2)-substituted sulfonamides, process for their preparation and use as thrombin inhibitors | F.HOFFMANN-LA ROCHE & CO. AKTIENGESELLSCHAFT (CH) | 1993-09-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311175-A1 | MASS TAGS FOR QUANTITATIVE ANALYSES | SRMS, PTMS, TMT1A | CYP2D6 1742/4885ITGB3 734/4885ITGA2B 1220/4885 |
| US-20070048752-A1 | Mass tags for quantitative analyses | SRMS, PTMS, TMT1A | CYP2D6 1742/4885ITGB3 734/4885ITGA2B 1220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.